Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng per milliliter during the seven years of the trial underwent a prostate biopsy at the end of the study. Biopsy revealed prostate cancer in 449...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2004-05, Vol.350 (22), p.2239-2246
Hauptverfasser:	Thompson, Ian M, Pauler, Donna K, Goodman, Phyllis J, Tangen, Catherine M, Lucia, M. Scott, Parnes, Howard L, Minasian, Lori M, Ford, Leslie G, Lippman, Scott M, Crawford, E. David, Crowley, John J, Coltman, Charles A
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biopsy Clinical trials Finasteride - therapeutic use General aspects Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical diagnosis Medical sciences Men Middle Aged Nephrology. Urinary tract diseases Prevalence Prostate - pathology Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - epidemiology Prostatic Neoplasms - pathology Prostatic Neoplasms - prevention & control Risk Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!